CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

By Reuters News


Overview

  • Biotechnology firm's Q3 revenue rose 12% yr/yr, slightly beating analyst expectations

  • Adjusted EPS for Q3 missed analyst expectations

  • Company raised full-year 2026 revenue guidance


Outlook

  • Vertex raises 2026 revenue guidance to $13.15 bln-$13.25 bln from $13.1 bln-$13.2 bln

  • Company expects $500 mln or more in 2026 revenue from CASGEVY and JOURNAVX combined


Result Drivers

  • CF THERAPIES - Revenue growth was driven by continued performance of cystic fibrosis therapies, including strong US demand and new initiations of ALYFTREK, as well as higher realized net prices and expanded reimbursement in additional countries

  • DIVERSIFICATION - Growth was supported by increased contributions from newer products such as CASGEVY, JOURNAVX, and PALSONIFY, reflecting diversification beyond cystic fibrosis

  • CRINETICS ACQUISITION EXPENSES - Net income declined year-over-year mainly due to expenses related to the Crinetics Pharmaceuticals acquisition, including compensation and transaction costs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$3.44 bln

$3.42 bln (25 Analysts)

Q3 Adjusted EPS

Miss

$4.76

$4.79 (17 Analysts)

Q3 EPS

$2.56

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Reuters Recommended Reads

  • Nov 2 - Syndax Pharmaceuticals Q3 revenue rises 82% on cancer drug sales

  • Nov 2 - IDEXX raises forecast, betting diagnostics can offset weak vet visits

  • Nov 2 - Deutsche Bank upgrades US tech, says selloff has gone too far


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.